Search Results
Dec 09, 2025, 08:00 ET Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and
More news about: Ginkgo Bioworks
Dec 09, 2025, 07:52 ET Antero Midstream Announces Launch of $500 Million Offering of Senior Notes
Special Mandatory Redemption Outside Date, the HG Purchase Agreement is terminated according to its terms without the closing of the HG Acquisition or (iii) Antero Midstream Partners determines based on its reasonable judgment that the HG Acquisition will not close prior to the Special Mandatory Redemption
More news about: Antero Midstream Corporation
Dec 09, 2025, 07:50 ET US Air Force Awards ThroughPut.ai Phase III Contract for "Aircraft Availability Optimization"
ghPut.AI announces it has been awarded its second SBIR Phase III contract focused on "
More news about: ThroughPut Inc.
Dec 09, 2025, 07:30 ET Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL
LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated PatientsORLANDO, Fla., Dec.
More news about: American Society of Hematology
Dec 09, 2025, 07:30 ET Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia
cells need to grow and activate, the drug helps rid the body of the problematic cells and prevent new ones from developing.VAYHIT2 was a phase III randomized controlled trial conducted in the United States and 23 other countries. It enrolled 152 patients with ITP who had either not responded to
More news about: American Society of Hematology
Dec 09, 2025, 07:00 ET Northstar Adds to Working Capital Reserves via Several Initiatives
shingles into their component parts in the inaugural commercial facility in Calgary; (ii) the enhancement of the Company's working capital reserves; (iii) the intended use of proceeds of the Financing and of the ERA Milestone 3 payment; (iv) the expected timing of, and the Company's ability to meet, the
More news about: Northstar Clean Technologies Inc.
Dec 09, 2025, 07:00 ET Saviynt Raises $700M at Approximately $3B Valuation in KKR-Led Round to Establish Identity Security as the Foundation for the AI Era
the company scale its identity security offering globally. The investment will be made primarily through KKR's Next Generation Technology Growth Fund III.Piper Sandler served as exclusive financial advisor to Saviynt, and Cooley LLP served as legal counsel to Saviynt. Latham & Watkins LLP served
More news about: Saviynt
Dec 09, 2025, 06:00 ET Hyperscale Data Bitcoin Treasury at Approximately $75 Million
building its long-term reserve position."We are very proud of the progress the Company has made towards its overall goal," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "The recent price action of Bitcoin has only further validated the Company's belief in Bitcoin
More news about: Hyperscale Data Inc.
Dec 09, 2025, 05:33 ET Ashika Investment Managers launches Ashika Mid & Small Cap Fund, an open-ended Category III AIF
Ashika Investment Managers Pvt. Ltd. has received node from SEBI for launch of the Ashika Mid & Small Cap Fund, an open-ended Category III AIF which is now open for subscription. Ashika Mid & Small Cap fund is designed to capture India's strongest emerging mid- and small-cap
More news about: Ashika Group
Dec 09, 2025, 05:00 ET FORT POINT CAPITAL EXITS INVESTMENT IN PORTFOLIO COMPANY, JONES LAKE MANAGEMENT
repeatable process to drive durable value, showcased in over 50 acquisitions since its inception. Fort Point is currently investing from FPC Small Cap Fund III. To learn more, please visit
More news about: Fort Point Capital
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
encouraging results, birelentinib has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). The global multicenter Phase III study in r/r CLL/SLL is currently ongoing.About Golidocitinib (DZD4205)Golidocitinib is currently the first and only Janus kinase
More news about: Dizal Pharmaceutical
Dec 09, 2025, 03:30 ET Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
on treatments for patients affected by glomerular diseases such as Alport Syndrome, FSGS and diabetic kidney disease.William Newsome III, Chief Executive Officer of Fibrocor Therapeutics, said: "The formation of Fibrocor's Clinical Advisory Board marks a significant milestone as we
More news about: Fibrocor Therapeutics
Dec 09, 2025, 02:50 ET Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025
ongoing phase III clinical trial in the perioperative setting, cadonilimab combined with chemotherapy as a first-line treatment for advanced gastric cancer (with survival benefits across the PD-L1 expression levels) has been approved for commercialization in China. Additionally, a pivotal phase III trial exploring
More news about: Akeso, Inc.
Dec 08, 2025, 21:02 ET Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by Professor Shun Lu from Shanghai Chest Hospital. The study evaluates ivonescimab (a
More news about: Akeso, Inc.
Dec 08, 2025, 19:00 ET Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly,
More news about: Innovent Biologics
Dec 08, 2025, 17:31 ET Acute on Chronic Liver Failure Market Set to Grow by 2034 as Novel Therapeutic Approaches Enter Clinical Pipeline | DelveInsight
equilibrium, making it an essential therapy for patients with hypovolemia or hypoalbuminemia.Currently, the product is being investigated in the Phase III APACHE clinical trial, which is evaluating the effect of plasma exchange with 5% human serum albumin on short-term survival in high-risk ACLF patients,
More news about: DelveInsight Business Research, LLP
Dec 08, 2025, 17:30 ET Alexander & Baldwin to be Taken Private in $2.3 Billion Transaction
relating to the merger that could be instituted against the Company or its directors or officers, including the effects of any outcomes related thereto, (iii) the risk that disruptions from the merger will harm the Company's business, including current plans and operations, including during the pendency of
More news about: Alexander & Baldwin
Dec 08, 2025, 17:28 ET Borr Drilling Announces Agreement to Acquire Five Premium Jack-Up Rigs
of an additional $150 million of the Company's existing 10.375% Senior Secured Notes due 2030; (ii) a $150 million seller's credit due in 2032; and (iii) an $85 million equity raise. The two rigs under bareboat charters will be placed into the Senior Secured Notes' restricted group which secures the Company's
More news about: Borr Drilling Limited
Dec 08, 2025, 16:43 ET Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)
said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. "The planned Phase IIb trial is designed to determine the optimal dose for a Phase III trial and to assess CS1's potential to meaningfully reduce pulmonary vascular resistance and improve functional capacity when added to today's standard
More news about: Cereno Scientific
Dec 08, 2025, 16:40 ET Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)
said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. "The planned Phase IIb trial is designed to determine the optimal dose for a Phase III trial and to assess CS1's potential to meaningfully reduce pulmonary vascular resistance and improve functional capacity when added to today's standard
More news about: Cereno Scientific
Dec 08, 2025, 16:13 ET Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: (i) septicemia; (ii) infective endocarditis; (iii) skin and skin structure infections; (iv) bone infections; and (v) lower respiratory tract infections.The name TYZAVAN™ stands for
More news about: Hikma Pharmaceuticals USA Inc.
Dec 08, 2025, 13:00 ET Moutai Returns to its Origin of World Fame, 110 Years from its Debut on Panama Expo
III. Toasting at "Moutai Night": Crafting Shared Value Through AromaOn the evening of December 7, Kweichow Moutai hosted a Moutai Night to commemorate
More news about: Moutai
Dec 08, 2025, 09:00 ET Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of Progenity, Inc. n/k/a Biora Therapeutics, Inc. common stock - BIORQ
SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION, CERTIFICATION OF SETTLEMENT CLASS, AND PROPOSED SETTLEMENT; (II) SETTLEMENT FAIRNESS HEARING; AND (III) MOTION FOR AN AWARD OF ATTORNEYS' FEESAND REIMBURSEMENT OF LITIGATION EXPENSESTO: All persons and entities that
More news about: Glancy Prongay & Murray LLP
Dec 08, 2025, 09:00 ET Shareholders that lost money on Skye Bioscience, Inc. (SKYE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
effective than defendants had led investors to believe; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.DEADLINE: January 16, 2026 Shareholders
More news about: The Gross Law Firm
Dec 08, 2025, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 30, 2026 in DeFi Technologies Lawsuit - DEFT
treasury companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly,
More news about: The Gross Law Firm